PTAB denies Coherus' Humira IPR challenge

Coherus BioSciences Inc. (NASDAQ:CHRS) lost $2.55 to $25.60 on Monday after the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office denied its inter partes review petition challenging U.S. Patent No. 9,114,166 covering Humira adalimumab from AbbVie Inc. (NYSE:ABBV). PTAB disagreed with Coherus' argument that the formulation described in the patent claims was obvious from prior art.

In May, PTAB instituted another IPR petition in which Coherus challenged another Humira patent (see BioCentury Extra, May 17). ...